<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306462</url>
  </required_header>
  <id_info>
    <org_study_id>05-12-27-01</org_study_id>
    <nct_id>NCT00306462</nct_id>
  </id_info>
  <brief_title>Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor</brief_title>
  <official_title>Randomized Double-Blinded Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor Between 24 to 32 6/7 Weeks' Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Hypothesis:

      Acute tocolysis (48 hours) using oral nifedipine is more effective than intravenous magnesium
      sulfate in prolonging pregnancy in women with preterm labor with intact membranes between 24
      and 32 6/7 weeks' gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To compare the efficacy of oral nifedipine versus IV magnesium sulfate on the rate of preterm
      delivery at &lt;37 weeks in women with preterm labor between 24 and 32 6/7 weeks gestation.

      Secondary Objective:

        1. To compare maternal side effects between the two tocolytic agents

        2. To compare neonatal morbidities between the two study groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No enrollment in past year, lack of interest
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery &lt;37 weeks' gestation, Delivery &lt;34 weeks' gestation, Delivery &lt;32 weeks' gestation</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal complications associated with each drugs. Neonatal morbidities associated with prematurity</measure>
    <time_frame>4 years and 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Premature Birth</condition>
  <condition>Premature Labor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous magnesium sulfate or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral nifedipine or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is &lt; 6/hour.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Nifedipine or placebo</intervention_name>
    <description>Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is &lt; 6/hour.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Oral procardia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in preterm labor between 24 to 32 6/7 weeks' gestation with intact membranes
             with an age range of 15 to 50 years old.

        Exclusion Criteria:

          -  Cervical dilatation of ≥ 6 cm

          -  Maternal contraindication to tocolysis

          -  Known fetal anomalies

          -  Suspected chorioamnionitis

          -  Nonreassuring fetal heart tracing

          -  Vaginal bleeding due to placenta previa or abruptio placenta

          -  Preterm premature rupture of membranes

          -  Prolapsed membranes

          -  Human immunodeficiency virus positive

          -  Multiple gestation

          -  Patients on procardia within 24 hours of po intake

          -  Magnesium sulfate tocolysis prior to randomization

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baha Sibai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000;(2):CD000065. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD000065.</citation>
    <PMID>10796110</PMID>
  </reference>
  <reference>
    <citation>Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev. 2002;(4):CD001060. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD001060.</citation>
    <PMID>12519550</PMID>
  </reference>
  <reference>
    <citation>Huddleston JF, Sanchez-Ramos L, Huddleston KW. Acute management of preterm labor. Clin Perinatol. 2003 Dec;30(4):803-24, vii. Review.</citation>
    <PMID>14714923</PMID>
  </reference>
  <reference>
    <citation>King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev. 2003;(1):CD002255. Review. Update in: Cochrane Database Syst Rev. 2014;6:CD002255.</citation>
    <PMID>12535434</PMID>
  </reference>
  <reference>
    <citation>Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol. 1993 Jul;169(1):97-102.</citation>
    <PMID>8333483</PMID>
  </reference>
  <reference>
    <citation>Papatsonis DN, Kok JH, van Geijn HP, Bleker OP, Adèr HJ, Dekker GA. Neonatal effects of nifedipine and ritodrine for preterm labor. Obstet Gynecol. 2000 Apr;95(4):477-81.</citation>
    <PMID>10725475</PMID>
  </reference>
  <reference>
    <citation>Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin Perinatol. 2001 Aug;25(4):236-47. Review.</citation>
    <PMID>11561911</PMID>
  </reference>
  <results_reference>
    <citation>Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol. 1993 Oct;169(4):960-4.</citation>
    <PMID>8238157</PMID>
  </results_reference>
  <results_reference>
    <citation>Haghighi L. Prevention of preterm delivery: nifedipine or magnesium sulfate. Int J Gynaecol Obstet. 1999 Sep;66(3):297-8.</citation>
    <PMID>10580682</PMID>
  </results_reference>
  <results_reference>
    <citation>Larmon JE, Ross BS, May WL, Dickerson GA, Fischer RG, Morrison JC. Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. Am J Obstet Gynecol. 1999 Dec;181(6):1432-7.</citation>
    <PMID>10601925</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <last_update_submitted>November 6, 2009</last_update_submitted>
  <last_update_submitted_qc>November 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Baha Sibai, MD/Professor</name_title>
    <organization>University of Cincinnati</organization>
  </responsible_party>
  <keyword>Premature Labor</keyword>
  <keyword>Premature Birth</keyword>
  <keyword>Magnesium sulfate</keyword>
  <keyword>Nifedipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 14, 2011</submitted>
    <returned>November 23, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

